Compare EZGO & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EZGO | TVRD |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | 12 |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.4M | 27.5M |
| IPO Year | 2020 | N/A |
| Metric | EZGO | TVRD |
|---|---|---|
| Price | $0.90 | $2.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 98.3K | ★ 6.5M |
| Earning Date | 07-01-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $1.50 |
| 52 Week High | $3.30 | $43.65 |
| Indicator | EZGO | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 36.58 | 38.25 |
| Support Level | $0.88 | $1.50 |
| Resistance Level | $1.34 | $4.32 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 5.66 | 2.39 |
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.